Coherus BioSciences | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Coherus BioSciences
- Double Formation
* Support=0 | EMA 20 | Area DIsclosure | Subdivision 1
* Neckline | Pattern Alignment At 2.40
- Triple Formation
* Entry Bias Hypothesis | Entry Area | Subdivision 2
* Retracement | 0.5. 0.236 & 0
* Angle 1 | 3,4,5 Wave Template | Subdivision 3
Active Sessions On Relevant Range & Elemented Probabilities;
London(Upwards) - NYC(Downwards)
Conclusion | Trade Plan Execution & Risk Management On Demand;
Overall Consensus | Neutral
CHRS trade ideas
CHRS - upcoming catalyst - breakout ahead ?Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
This is not a financial advice!
Upcoming catalyst in 2024
A few block buys last months
Short Float 26.86 %
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Key level is 2.5 - needs to get broken.
Keep an eye on 2.85 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 2.15
TP approx. 3.7
Most info on the chart.
Trade carefully!
Junshi Biosciences and Coherus Announce Positive Interim OverallCHRS: Junshi Biosciences
2021-12-13 07:00:00
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
COHERUS cracking $21 will unleash major bullish potentialCOHERUS BIOSCIENCES Inc., NASDAQ:CHRS , is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.
CHRS, Stochastic Oscillator left the overbought zone on Oct 09This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 63 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 58 of them led to successful outcomes. Odds of Success: 90%. Current price $18.48 crossed the resistance line at $18.65 and is trading between $18.65 resistance and $18.00 support lines. Throughout the month of 09/09/20 - 10/09/20, the price experienced a -1% Downtrend, while the week of 10/02/20 - 10/09/20 shows a +10% Uptrend.
Bearish Trend Analysis
CHRS moved below its 50-day Moving Average on October 09, 2020 date and that indicates a change from an upward trend to a downward trend.
The 10-day Moving Average for CHRS crossed bearishly below the 50-day moving average on October 01, 2020. This indicates that the trend has shifted lower and could be considered a sell signal. Tickeron A.I. detected that in 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where Apple declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for CHRS entered a downward trend on September 16, 2020. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
CHRS, Stochastic Oscillator left the overbought zone on June 29This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 61 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 52 of them led to successful outcomes. Odds of Success: 85%.
Current price $17.86 crossed the resistance line at $17.45 and is trading between $19.50 support and $17.45 resistance lines. Throughout the month of 05/28/20 - 06/29/20, the price experienced a -4% Downtrend, while the week of 06/22/20 - 06/29/20 shows a +0.73% Uptrend.
CHRSSignal -Potencial Short
News-Earning Report- Coherus BioSciences reports 4Q loss
Volumen 2.38M, Float 42.25M, Avg Vol (10 day) 780k, Avg Vol (3 month) 646k, NasdaqGM, Healthcare-Biotechnology
Waiting 1 red day!!!!
Potencial Short- Waiting for signal- BreakDown trend line!
Break Trend line!!!! Lower-Low
Waiting for opportunity!
Don't leave overnight!!!!
gyazo.com UpComing News